|
FFF Enterprises, in partnership with Roche Laboratories, announces the availability of Tamiflu to help you prepare and stockpile for widespread influenza outbreaks.
To place your Tamiflu order, please call FFF's Wow! Customer Care Department at 800-843-7477.
Tamiflu treats flu at its source by attacking the virus that causes the flu, rather than simply masking symptoms. Tamiflu is the only anti-flu pill effective against all common strains of influenza types A and B.
Tamiflu is indicated for the treatment of uncomplicated acute illness due to influenza infection in patients 1 year of age and older who have been symptomatic for no more than 2 days.
Tamiflu is also indicated for the prophylaxis of influenza in adult patients and adolescents 13 years and older; safety and efficacy have been demonstrated for up to 6 weeks.
In treatment studies in adult patients, adverse events occurring more frequently in patients taking Tamiflu® (oseltamivir phosphate) compared with placebo (incidence =1%) were nausea, vomiting, bronchitis, insomnia and vertigo. No information is available regarding treatment of influenza in patients with any medical condition sufficiently severe or unstable to be considered at imminent risk of requiring hospitalization.
In prophylaxis studies in adult patients and adolescents 13 years and older, adverse events were qualitatively very similar to those seen in the treatment studies, despite a longer duration of dosing. Events reported more frequently in subjects receiving Tamiflu compared to subjects receiving placebo in prophylaxis studies included nausea, vomiting, diarrhea, abdominal pain, dizziness, headache, insomnia, vertigo and fatigue.
There is no evidence for the efficacy of Tamiflu in any illness other than influenza types A and B. Treatment efficacy in high-risk patients has not been established, and there were no differences in the incidence of complications between treatment and placebo groups in this population. The safety and efficacy of repeated treatment or prophylaxis courses have not been studied.
Vaccination is considered the first line of defense against influenza.
|
